← Leaderboards
Matthew Volm
New York University School Of Medicine
$84,024
Attributed
$84,024
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$84,024 · 4
By mechanism
M01$84,024 · 4
Top collaborators
No co-investigators on record.
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Eva Hernando$15,270,218
- Kwok Kin Wong$31,472,345
- Ruth E. Lehmann$10,490,053
- Howard S Hochster$9,390,994
- Markus Schober$8,962,767
Others in their field
Top investigators on “Human Therapy Evaluation”
- Lawrence Corey · Fred Hutchinson Cancer Center$368,153,539
- David Heimbrook · Leidos Biomedical Research, Inc.$241,598,366
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barbara Driver · Westat, Inc.$206,347,735
- Carol Nesel · Westat$188,148,170
- Constance Ann Benson · University Of California, San Diego$179,950,251
Research focus
Human Therapy EvaluationClinical ResearchHuman SubjectBreast NeoplasmsNeoplasm /Cancer ChemotherapyPaclitaxelFemaleCyclophosphamideDrug Screening /EvaluationLymphomaMetastasisMolecular OncologyMonoclonal AntibodyNeoplasm /Cancer ImmunotherapyNeoplasm /Cancer Relapse /RecurrenceNeoplasm /Cancer SurgeryOncogenesP53 Gene /ProteinPrednisoneRecombinant ProteinsAids Related Neoplasm /CancerVincristineApoptosisCarcinoma
Grant awards (16)
MULTIMODALITY THERAPY FOR LOCALLY ADVANCED BREAST CANCER$0
M01 · FY2002 · RR
RHUMAB HER2 IN RELAPSED BREAST CANCER PATIENTS W/ 2 PRIOR CHEMOTHERAPY REGIMENS$0
M01 · FY2002 · RR
LAB STUDY TO EVALUATE PACLITAXELS CELLULAR &MOLECULAR EFFECTS IN BREAST CANCER$0
M01 · FY2002 · RR
DOXIL, CYCLOPHOSPHAMIDE, VINCRISTINE AND PREDNISONE FOR AIDS LYMPHOMA$0
M01 · FY2002 · RR
MULTIMODALITY THERAPY FOR LOCALLY ADVANCED BREAST CANCER$0
M01 · FY2001 · RR
DOXIL, CYCLOPHOSPHAMIDE, VINCRISTINE AND PREDNISONE FOR AIDS LYMPHOMA$0
M01 · FY2001 · RR
LAB STUDY TO EVALUATE PACLITAXELS CELLULAR &MOLECULAR EFFECTS IN BREAST CANCER$0
M01 · FY2001 · RR
RHUMAB HER2 IN RELAPSED BREAST CANCER PATIENTS W/ 2 PRIOR CHEMOTHERAPY REGIMENS$0
M01 · FY2001 · RR
MULTIMODALITY THERAPY FOR LOCALLY ADVANCED BREAST CANCER$21,006
M01 · FY2000 · RR
DOXIL, CYCLOPHOSPHAMIDE, VINCRISTINE AND PREDNISONE FOR AIDS LYMPHOMA$21,006
M01 · FY2000 · RR
LAB STUDY TO EVALUATE PACLITAXELS CELLULAR &MOLECULAR EFFECTS IN BREAST CANCER$21,006
M01 · FY2000 · RR
RHUMAB HER2 IN RELAPSED BREAST CANCER PATIENTS W/ 2 PRIOR CHEMOTHERAPY REGIMENS$21,006
M01 · FY2000 · RR
LAB STUDY TO EVALUATE PACLITAXELS CELLULAR &MOLECULAR EFFECTS IN BREAST CANCER$0
M01 · FY2000 · RR
RHUMAB HER2 IN RELAPSED BREAST CANCER PATIENTS W/ 2 PRIOR CHEMOTHERAPY REGIMENS$0
M01 · FY2000 · RR
DOXIL, CYCLOPHOSPHAMIDE, VINCRISTINE AND PREDNISONE FOR AIDS LYMPHOMA$0
M01 · FY2000 · RR
MULTIMODALITY THERAPY FOR LOCALLY ADVANCED BREAST CANCER$0
M01 · FY2000 · RR